Oct 1 (Reuters) – CAMP4 Therapeutics Corp: * CAMP4 THERAPEUTICS INITIATES GLP TOXICOLOGY STUDIES FOR CMP-SYNGAP-01 Source text: Further company coverage:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

The post BRIEF-Camp4 Therapeutics Initiates GLP Toxicology Studies For Cmp-Syngap-01 appeared first on The Sunday Guardian.

See Full Page